MedTrace Logo

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

NCT07517068 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-08

No results posted yet for this study

Summary

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Conditions

  • Hypoxemia
  • Acute Mountain Sickness (AMS)
  • Inflammation
  • Immune Response

Interventions

DRUG

ACETAZOLAMIDE oral capsule

Acetazolamide is administered orally in pill form at a 125 mg dose taken twice per day (morning and evening) starting 2 days before ascent to high altitude and each day while at high altitude.

DEVICE

Placebo Arm

Not utilization of Acetazolamide (ACZ) oxygenation (SpO2) or any other supportive measurement will be used with this group.

Sponsors & Collaborators

  • University of California, Riverside

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2026-06-15
Completion
2026-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07517068 on ClinicalTrials.gov